Vonoprazan - Takeda
Alternative Names: Lupivon; TAK-438; TAKECAB; VOCINTI; Vocinti; VONOPION®; Vonoprazan fumarate; VONOSAP®; VOQUEZNA; VOQUEZNA DUAL PAK; VOQUEZNA TRIPLE PAKLatest Information Update: 30 Sep 2024
At a glance
- Originator Takeda
- Developer Phathom Pharmaceuticals; Takeda
- Class Amines; Anti-inflammatories; Antibacterials; Antiulcers; Pyridines; Pyrroles; Small molecules; Sulfonamides
- Mechanism of Action Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Reflux oesophagitis
- Phase III Gastrointestinal disorders
Most Recent Events
- 18 Sep 2024 Lupin enters into a non-exclusive patent license agreement with Takeda to commercialize Vonoprazan Tablets in India
- 13 Sep 2024 Phathom Pharmaceuticals completes a phase I pharmacokinetic trial (In volunteers) in the US (PO, Tablet) (NCT06391177)
- 18 Jul 2024 Registered for Gastro-oesophageal reflux (In adults) in USA (PO)